AUTHORS
Bryan Sisk, MD, Ionela Iacobas Jr, MD2, Shelley Crary, MD, MS3, Joyce Teng4, Eulalia Baselga5, Ahmad Al-Huniti, MD6, Alexandra Borst7, Adrienne Hammill, MD PhD8, Alessandro Mussa9, Satyamaanasa Polubothu10, Emmanuel Seront11, Beth Apsel Winger, MD, PhD12, Vivian Y Chang, MD, MS13, Beth Drolet14, Michael H White, MD, MSc15, Andrea Diociaiuti16, Manuel Gomez Tellado17, Melanie Jackson18, Michael Kelly19, Camille Skaer20, Paloma Triana21, Denise Adams, MD22, Whitney Eng Jr, MD, MPH23, Simone Hettmer24, Alan Irvine25, Alok Kothari26, Bisola Laguda27, Kathryn Lemberg28, Taizo Nakano Jr, MD29, Maurizio Pacilli30, Anthony Penington31, Kristy Pilbeam32, Susan Russell33, Laura Scardamaglia34, Martin A. Robledo35, Xuemin Gu36, Thao Nguyen37, Sonia Singh38, Brenton G. Mar39, Juan Carlos Lopez-Gutierrez40
AFFILIATIONS
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Baylor College Of Medicine / Texas Children's Hospital, Houston, Texas, United States
3 Arkansas Hospital/ University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
4 Stanford University, Palo Alto, California, United States
5 Hospital Sant Joan de Deu, Madrid, Spain
6 The Mayo Clinic, Rochester, Minnesota, United States
7 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
8 Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
9 A.O.U. Città della Salute e della Scienza di Torino (University of Torino), Torino, Italy
10 Great Ormond Street Hospital Foundation Trust, London, United Kingdom
11 UC Louvain, Louvain-la-Neuve, Belgium
12 UCSF Birthmarks and Vascular Center, San Francisco, California, United States
13 University of California, Los Angeles Health, Los Angeles, California, United States
14 University of Wisconsin, Madison, Wisconsin, United States
15 Emory School of Medicine, Aflac Cancer & Blood Disorders Center, Atlanta, Georgia, United States
16 Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy
17 Hospital Universitario de A Coruna, A Coruna, Spain
18 Children's Health Queensland Hospital and Health Service, South Brisbane, Australia
19 The Cleveland Clinic, Cleveland, Ohio, United States
20 Washington University School of Medicine, St. Louis, Missouri, United States
21 Hospital Universitario La Paz, Madrid, Spain
22 Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
23 Seattle Children's Hospital, Seattle, Washington, United States
24 Halle University Hospital, Halle, Germany
25 Children's Health Ireland at Crumlin, Dublin, Ireland
26 Phoenix Children's Hospital, Phoenix, Arizona, United States
27 Chelsea and Westminster Hospital, London, United Kingdom
28 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
29 Children's Hospital Colorado, Aurora, Colorado, United States
30 Monash Children's Hospital, Melbourne, Australia
31 Murdoch Children's Research Institute, Parkville, Australia
32 Corewell Health Research Institute, Royal Oak, Michigan, United States
33 Sydney Children’s Hospital, Randwick, Australia
34 Royal Melbourne Hospital, Melbourne, Australia
35 Relay Therapeutics, Cambridge, Massachusetts, United States
36 Relay Therapeutics, Cambridge, Massachusetts, United States
37 Relay Therapeutics, Cambridge, Massachusetts, United States
38 Relay Therapeutics, Cambridge, Massachusetts, United States
39 Relay Therapeutics, Cambridge, Massachusetts, United States
40 Hospital Universitario La Paz, Madrid, Spain
ABSTRACT
Background and Significance
Somatic gain-of-function mutations in the PIK3CA gene can lead to the development of rare, heterogeneous vascular malformations including lymphatic malformations (LMs), and PIK3CA-related overgrowth spectrum (PROS). These noncancerous lesions may be managed with local treatments such as surgery and sclerotherapy, or in patients with more advanced or extensive disease, sirolimus and non-mutant-selective PI3Kα inhibitors may be administered. Use of systemic therapies in patients is frequently limited by drug-related adverse effects; in particular, inhibition of wild-type PI3Kα may cause significant toxicity, including hyperglycemia, diarrhea, stomatitis, rash, and growth delay.
Zovegalisib is a novel, allosteric, mutant-selective oral PI3Kα inhibitor designed to preferentially target mutant PI3Kα and improve tolerability. In PIK3CA-mutant genetically engineered and xenograft mouse models, zovegalisib demonstrated greater lesion regression and less insulin induction across clinically relevant dose levels than alpelisib, a non-mutant-selective inhibitor.
ReInspire (NCT06789913) is an ongoing, global, Phase 2 study in patients with PIK3CA-driven vascular malformations to assess the safety, pharmacokinetics, recommended adult (fixed) and pediatric (weight-based) dosing, and efficacy of zovegalisib based on target lesion volume and clinical outcome assessments (COAs). The design of this study, including dose selection, was informed by clinical data from the first-in-human study of zovegalisib in adult patients with advanced solid tumors, including breast cancer.
Study Design and Methods
ReInspire is a 3-part study evaluating the safety and efficacy of zovegalisib in ~277 patients two years and older with PIK3CA-driven vascular malformations. Zovegalisib is administered orally in continuous cycles. The primary endpoints are safety, tolerability, recommended Phase 2 dose (RP2D) selection, and efficacy of zovegalisib per volumetric reduction on MRI (≥20% reduction from baseline to Week 24 in sum target lesion volume) by blinded independent central review. Other endpoints include duration of response and change in age-appropriate COAs.
Patients are enrolled in a staggered fashion by age, beginning with adults and adolescents ≥12 years (Group 1), and then extended to pediatric participants 6 to <12 years (Group 2) and 2 to <6 years (Group 3), based on review of cumulative clinical data.
Part 1, the dose-finding portion, initiated with randomization of 32 Group 1 patients to one of three dose levels (100, 300, 400 mg BID) with stratification per prior alpelisib use, and is followed by ongoing weight-based dose escalation using a Bayesian optimal interval design in Group 2, and Group 3. Part 2 is a basket-style dose expansion that evaluates the clinical activity of zovegalisib at RP2D(s) in cohorts of 20 participants, each based on Part 1 findings. Part 2 is currently enrolling Group 1 participants with dose expansion cohorts including 300 mg BID and 400 mg QD. Depending on the results of Parts 1 and 2, Part 3 may be a randomized study in patients 6 years and older.
To enroll, patients are required to have a clinical diagnosis of PROS or a vascular malformation within the ISSVA classifications, and the majority must have a documented activating PIK3CA mutation per local assessment of lesional tissue and/or cell-free DNA from the lesion or blood. Patients with other known pathogenic somatic or germline driver mutations (e.g., TIE2 (TEK) and AKT1) are ineligible. Patients must be a candidate for investigational systemic therapy; have severe, symptomatic, and/or progressive disease; and ≥1 target lesion amenable for volumetric assessment. Additionally, patients who have received disease-directed therapy must undergo a washout period for systemic treatment and local therapies including radiation, surgery and other procedures. Patients with Type 1 or 2 diabetes requiring antihyperglycemic medication or fasting plasma glucose ≥140 mg/dL, or glycosylated hemoglobin (HbA1c) ≥7.0% (≥53 mmol/mol) are ineligible.
Statistical analyses will be primarily descriptive in nature in Parts 1 and 2, with statistical comparisons between zovegalisib and placebo at Week 24 in Part 3.
ReInspire is open to enrollment. Patients ≥6 years are now enrolling. For more information, contact clinicaltrials@relaytx.com.
DISCLOSURES
Bryan Sisk, MD: VasqueBio - Consultancy (Includes expert testimony); Palvella Therapeutics - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); OnCusp Therapeutics - Consultancy (Includes expert testimony); OnKure Therapeutics - Consultancy (Includes expert testimony); Relay Therapeutics - Consultancy (Includes expert testimony); Gilead Sciences - Consultancy (Includes expert testimony); Palinos - Consultancy (Includes expert testimony); Kaken Pharmaceuticals - Consultancy (Includes expert testimony)